Effect of microRNA-101 on proliferation and apoptosis of human osteosarcoma cells by targeting mTOR

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 34, Issue 6, 2014, Pages 889-895

  Lin, Song ^a   Shao, Nan nan ^b   Fan, Lei ^a   Ma, Xiu cai ^a   Pu, Fei fei ^a   Shao, Zeng wu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b ZHENGZHOU UNIVERSITY   (China)

Author keywords

apoptosis; miR 101; mTOR; osteosarcoma; proliferation

Indexed keywords

MICRORNA; MIRN101 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; RNA; TARGET OF RAPAMYCIN KINASE; TUMOR PROTEIN;

APOPTOSIS; BONE TUMOR; CELL PROLIFERATION; GENETICS; HUMAN; METABOLISM; OSTEOSARCOMA; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MICRORNAS; NEOPLASM PROTEINS; OSTEOSARCOMA; RNA, NEOPLASM; TOR SERINE-THREONINE KINASES;

EID: 84914146806     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-014-1369-y     Document Type: Article

References (29)

1. Kobayashi E, Hornicek FJ, Duan Z. MicroRNA involvement in osteosarcoma. Sarcoma, 2012,2012: 359739
2. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol, 2010,8(10):705–718
3. Ma O, Cai WW, Zender L, et al. MMP13, Birc2 (cIAP1), and Birc3 (cIAP2), amplified on chromosome 9, collaborate with p53 deficiency in mouse osteosarcoma progression. Cancer Res, 2009,69(6): 2559–2567
4. Bielack SS, Kempf-Bielack B, Delling G, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol, 2002,20(3):776–790
5. Ottaviani G, Jaffe N. The epidemiology of osteosarcoma. Cancer Treat Res, 2009,152:3–13
6. Ambros V. microRNAs: tiny regulators with great potential. Cell, 2001,107(7):823–826
7. Volk N, Shomron N. Versatility of microRNA biogenesis. PLoS One, 2011,6(5):e19391
8. Yan K, Gao J, Yang T, et al. MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS One, 2012,7(3):e33778
9. Fan L, Wu Q, Xing X, et al. MicroRNA-145 targets vascular endothelial growth factor and inhibits invasion and metastasis of osteosarcoma cells. Acta Biochim Biophys Sin (Chinese), 2012,44(5):407–414
10. Hu Z, Lin Y, Chen H, et al. MicroRNA-101 suppresses motility of bladder cancer cells by targeting c-Met. Biochem Biophys Res Commun, 2013,435(1):82–87
11. Zhang Y, Guo X, Xiong L, et al. MicroRNA-101 suppresses SOX9-dependent tumorigenicity and promotes favorable prognosis of human hepatocellular carcinoma. FEBS Lett, 2012,586(24):4362–4370
12. Huang F, Lin C, Shi YH, et al. MicroRNA-101 inhibits cell proliferation, invasion, and promotes apoptosis by regulating cyclooxygenase-2 in Hela cervical carcinoma cells. Asian Pac J Cancer Prev, 2013,14(10):5915–5920
13. Yin J, Wang M, Jin C, et al. miR-101 sensitizes A549 NSCLC cell line to CDDP by activating caspase 3-dependent apoptosis. Oncol Lett, 2014,7(2): 461–465
14. Xu Y, An Y, Wang Y, et al. miR-101 inhibits autophagy and enhances cisplatin-induced apoptosis in hepatocellular carcinoma cells. Oncol Rep, 2013,29(5):2019–2024
15. Wang R, Wang HB, Hao CJ, et al. MiR-101 is involved in human breast carcinogenesis by targeting Stathmin1. PLoS One, 2012,7(10):e46173
16. Fasolo A, Sessa C. Targeting mTOR pathways in human malignancies. Curr Pharm Des, 2012,18(19): 2766–2777
17. Zhao L, Teng B, Wen L, et al. mTOR inhibitor AZD8055 inhibits proliferation and induces apoptosis in laryngeal carcinoma. Int J Clin Exp Med, 2014,7(2):337–347
18. Marioni G, Staffieri A, Lora L, et al. mTOR expression and prognosis in elderly patients with laryngeal carcinoma: uni- and multi-variate analyses. Oral Oncol, 2012,48(6):530–534
19. Zhang B, Pan X, Cobb GP, et al. microRNAs as oncogenes and tumor suppressors. Dev Biol, 2007,302(1):1–12
20. Medina PP, Nolde M, Slack FJ. OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature, 2010,467(7311):86–90
21. Kong W, He L, Coppola M, et al. MicroRNA-155 regulates cell survival, growth, and chemosensitivity by targeting FOXO3a in breast cancer. J Biol Chem, 2010,285(23):17 869–17 879
22. Costinean S, Zanesi N, Pekarsky Y, et al. Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci USA, 2006,103(18):7024–7029
23. Chandramouli A, Onyeagucha BC, Mercado-Pimentel ME, et al. MicroRNA-101 (miR-101) post-transcriptionally regulates the expression of EP4 receptor in colon cancers. Cancer Biol Ther, 2012,13(3):175–183
24. Zhang JG, Guo JF, Liu DL, et al. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2. J Thorac Oncol, 2011,6(4):671–678
25. Chen K, Fan W, Wang X, et al. MicroRNA-101 mediates the suppressive effect of laminar shear stress on mTOR expression in vascular endothelial cells. Biochem Biophys Res Commun, 2012,427(1):138–142
26. Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell, 2012,149(2):274–293.
27. Gobin B, Battaglia S, Lanel R, et al. NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and tumor development in vivo with an improved survival rate. Cancer Lett, 2014,344(2):291–298
28. Grabinski N, Ewald F, Hofmann BT, et al. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells. Mol Cancer, 2012,11:85
29. Li M, Sun H, Song L, et al. Immunohistochemical expression of mTOR negatively correlates with PTEN expression in gastric carcinoma. Oncol Lett, 2012,4(6):1213–1218